To Investigate the Pharmacokinetics, Safety, Tolerability and Efficacy of SHR-2524 Combined With Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) in an Open-label, Multicenter Phase I Clinical Trial
Latest Information Update: 05 May 2026
At a glance
- Drugs Bevacizumab (Primary) ; SHR 2524 (Primary)
- Indications Liver cancer
- Focus Pharmacokinetics
- Sponsors Suzhou Suncadia Biopharmaceuticals
Most Recent Events
- 29 Apr 2026 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Mar 2026 to 14 Apr 2026.
- 29 Apr 2026 Status changed from not yet recruiting to recruiting.
- 30 Mar 2026 New trial record